henry green @henrygreen25 Nov 24 @G_Commish s
Post# of 30066
Posted On: 11/28/2015 10:26:55 AM
henry green @henrygreen25 Nov 24
@G_Commish so the Avxl partnership was just them using Lympro for free? I'm getting you a dictionary for xmas. Team $ambs
Gerald Commissiong @G_Commish Nov 26
@henrygreen25 we believe strongly in Sigma 1
And here's why - Alzheimer’s Disease, Epilepsy and Parkinson’s
NEW YORK, NY, November 9, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL). On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s disease targeting sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.
http://www.anavex.com/?news=anavex-announces-...e%e2%80%8e
November 19, 2015 – “ANAVEX 2-73 demonstrated convincing data in three well-established and predictive preclinical anti-seizure models with potentially more favorable side effect profile than currently marketed epilepsy drugs,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex."
http://www.anavex.com/?news=anavex-to-present...ure-models
August 10, 2015 - Anavex Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research
"As a potential platform drug and the Company’s lead therapeutic, ANAVEX 2-73 targets misfolded proteins central to many neurodegenerative diseases , including Parkinson’s and Alzheimer’s. It is believed to enhance the body’s own cellular defense mechanisms through both sigma-1 and muscarinic receptors to return diseased cells to a pre-diseased or “homeostatic” state."
http://www.anavex.com/?news=anavex-awarded-gr...s-research
@G_Commish so the Avxl partnership was just them using Lympro for free? I'm getting you a dictionary for xmas. Team $ambs
Gerald Commissiong @G_Commish Nov 26
@henrygreen25 we believe strongly in Sigma 1
And here's why - Alzheimer’s Disease, Epilepsy and Parkinson’s
NEW YORK, NY, November 9, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL). On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s disease targeting sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.
http://www.anavex.com/?news=anavex-announces-...e%e2%80%8e
November 19, 2015 – “ANAVEX 2-73 demonstrated convincing data in three well-established and predictive preclinical anti-seizure models with potentially more favorable side effect profile than currently marketed epilepsy drugs,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex."
http://www.anavex.com/?news=anavex-to-present...ure-models
August 10, 2015 - Anavex Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research
"As a potential platform drug and the Company’s lead therapeutic, ANAVEX 2-73 targets misfolded proteins central to many neurodegenerative diseases , including Parkinson’s and Alzheimer’s. It is believed to enhance the body’s own cellular defense mechanisms through both sigma-1 and muscarinic receptors to return diseased cells to a pre-diseased or “homeostatic” state."
http://www.anavex.com/?news=anavex-awarded-gr...s-research
(0)
(0)